NCOA5 suppresses tumor progression and cisplatin resistance in non-small cell lung cancer by interfering with PRDX6 transcription
Biochemical Pharmacology · 2025
DOI: 10.1016/j.bcp.2025.117102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025. Verfasst von Dan-Ni Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Wenzhou Medical University, Basic Research Project of Wenzhou City.
Abstract (Originalsprache)
Cisplatin (CDDP)-based chemotherapy is an important treatment modality for non-small cell lung cancer (NSCLC), yet its efficacy is limited by the development of drug resistance. Chemoresistance is associated with aberrant lipid metabolism. We analyzed differentially expressed lipid metabolism-related genes based on public data and searched for a novel regulator of NSCLC chemoresistance. NCOA5, a regulator of cholesterol efflux, was found to be downregulated in CDDP-resistant NSCLC cells and surgically resected NSCLC tissues. Low NCOA5 expression was significantly associated with lymph node metastasis, TNM stage, and prognosis in NSCLC. NCOA5 knockdown increased the proliferation, invasion, and tumorigenesis of NSCLC cells. Overexpression of NCOA5 reversed the CDDP resistance of NSCLC cells both in vitro and in vivo. The chemosensitive effect of NCOA5 on CDDP-resistant NSCLC cells was impaired by N-acetylcysteine, an inhibitor of reactive oxygen species (ROS). Mechanistic investigations revealed that NCOA5 repressed PRDX6 expression by interfering with NRF2-mediated transactivation. Depletion of PRDX6 phenocopied the NCOA5-overexpressing cells and resulted in increased ROS generation and CDDP sensitivity. Furthermore, enforced expression of PRDX6 blunted the effects of NCOA5 on ROS production and CDDP sensitivity in NSCLC cells. Our data reveal a crucial role for NCOA5 in NSCLC progression and CDDP resistance. Thus, targeting the NCOA5/PRDX6 axis may be a promising strategy to overcome CDDP resistance in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.
- Graduate School of Wenzhou Medical University, Wenzhou, China.
- Department of Central Lab, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.
- Department of Thoracic Surgery, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China. Electronic address: hrs9900@wmu.edu.cn.
Förderung
- Wenzhou Medical University
- Basic Research Project of Wenzhou City
Zitieren
APA
Wu, D. N., Huang, P., Zhang, K. L., Chen, R. H., & Huang, R. S. (2025). NCOA5 suppresses tumor progression and cisplatin resistance in non-small cell lung cancer by interfering with PRDX6 transcription. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2025.117102
Vancouver
Wu DN, Huang P, Zhang KL, Chen RH, Huang RS. NCOA5 suppresses tumor progression and cisplatin resistance in non-small cell lung cancer by interfering with PRDX6 transcription. Biochemical Pharmacology. 2025. doi:10.1016/j.bcp.2025.117102
BibTeX
@article{Wu2025,
author = {Wu, Dan-Ni and Huang, Ping and Zhang, Kang-Liang and Chen, Rui-Heng and Huang, Ri-Sheng},
title = {NCOA5 suppresses tumor progression and cisplatin resistance in non-small cell lung cancer by interfering with PRDX6 transcription},
journal = {Biochemical Pharmacology},
year = {2025},
doi = {10.1016/j.bcp.2025.117102}
}
EUVIMED